- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04294706
Effects of Hemp Oil on Markers of Optimal Wellness, Stress Resilience and Recovery in Healthy Subjects
3. marts 2020 opdateret af: The Center for Applied Health Sciences, LLC
The purpose of this placebo-controlled, double-blind study is to determine the effects of a commercially available (i.e.
dietary supplement) Hemp Oil Extract product on various markers of physical and mental stress resilience, and perceived recovery from normal daily physical & mental stress.
Secondary purposes are to collect information on perceived appetite, mood, feelings of wellbeing, sleep quality, body composition and safety information via standard clinical chemistry panels of sera and plasma.
Studieoversigt
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
65
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Ohio
-
Canfield, Ohio, Forenede Stater, 44406
- The Center for Applied Health Sciences
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 55 år (Voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Subjects provide written and dated informed consent to participate in an IRB approved study.
- Subjects are in good health as determined by medical history and routine blood chemistries.
- Subjects are male or female between the ages of 18 and 55 (inclusive).
- Female subjects must agree to use barrier contraceptive methods during sexual intercourse for the duration of the study. All females will undergo pregnancy testing (urine HCG screen) before being screened and at each visit unless they present evidence of surgical sterilization by tubal ligation, bilateral oophorectomy or hysterectomy.
- Subjects have a Body Mass Index of 25-35.
- Subjects are willing and able to comply with the daily activity and supplement protocol.
- Subject is willing and able to comply with the visit schedule.
- Subjects are normotensive (resting systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg), have a normal resting heart rate (<90 per minute).
Exclusion Criteria:
- Subjects that currently exercise more than three times per week.
- Subject has used weight loss medications within the past three months of Screening visit.
- Subject is on thyroid medication at a dose that is not considered stable. Stable is defined as using the same dose consistently for at least 90 days.
- Subjects with any metabolic disorder including known electrolyte abnormalities, diabetes (or fasting glucose ≥126 mg/dL at the screening visit), unstable or unmanaged thyroid disease, or hypogonadism.
- Subjects with a history of hepato-renal, musculoskeletal, autoimmune, neurologic disease, or any other medical condition deemed exclusionary by the medical staff.
- Subjects taking anti-anxiety, anti-depressant, psychotropic hyperlipidemic, hypoglycemic, anti-coagulant or androgenic medications; nitrates/nitrate derivatives, and PDE-5 inhibitors; and other vasodilatory agents such as calcium channel blockers and beta blockers.
- Subject has an active gastrointestinal disorder such as peptic ulcer disease or malabsorption syndrome (mild lactose intolerance or gastroesophageal reflux diseases are acceptable).
- Subjects who have taken anabolic steroids, growth hormone, IGF-1 or other anabolic drugs within the past year.
- Subjects who are pregnant, trying to become pregnant, or who are nursing.
- Female participants who are < 120 days postpartum before enrolling.
- Subjects who have taken any nutritional supplements that may affect sleep, mood or healthy stress response (including but not limited to Ashwagandha, Valerian root, Melatonin, L-theanine, 5-HTP), or that may affect anabolic/catabolic hormone levels (e.g., androstenedione, DHEA, etc.) within four weeks prior to the start of the study.
- Subjects who have gained or lost more than 5 lbs within 30 days prior to the start of the study.
- Subjects with history of heart disease, peripheral vascular disorders or vaso-occlusive or vasospastic syndromes, psychiatric disorders, or history of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin.
- Subject has a recent history of (within 3 months of Screening Visit) or strong potential for alcohol or substance abuse. Alcohol abuse defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).
- Subject has been hospitalized within the past one-year for any mental or emotional illness.
- Subject has an active infection or sign/symptoms of an infection.
- Subject has dietary tendencies that may be representative of disordered eating (in the opinion of the Investigator).
- Subjects who had any known allergy to any of the ingredients in any of the test products.
- Subjects who are participating in other research studies.
- Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk.
- Subjects who smoked or used any tobacco or nicotine containing products within the past year.
- Subjects with syndromes or prescribed medications that may influence body composition, or CVD (e.g. prednisone, Ritalin, Adderall, GH); also protease inhibitors/antivirals (nucleic acid analogs).
- Subjects with orthopedic limitations or injuries that would preclude them from the physical activity intervention in this study.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Hemp arm
Randomly assignment to Hemp arm (60 mg/day of hemp oil extract x 6 weeks)
|
Hemp oil
|
Placebo komparator: Placebo arm
Randomly assigned to Placebo arm (60 mg/day of cellulose x 6 weeks)
|
Hemp oil
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Sleep quality
Tidsramme: baseline
|
A visual analog scale constructed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings.
|
baseline
|
Sleep quality
Tidsramme: week 3
|
A visual analog scale constructed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings.
|
week 3
|
Sleep quality
Tidsramme: week 6
|
A visual analog scale constructed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings.
|
week 6
|
Stress
Tidsramme: Baseline
|
A visual analog scale constructed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings.
|
Baseline
|
Stress
Tidsramme: Week 3
|
A visual analog scale constructed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings.
|
Week 3
|
Stress
Tidsramme: Week 6
|
A visual analog scale constructed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings.
|
Week 6
|
Well-being
Tidsramme: Baseline
|
A visual analog scale constructed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings.
|
Baseline
|
Well-being
Tidsramme: Week 3
|
A visual analog scale constructed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings.
|
Week 3
|
Well-being
Tidsramme: Week 6
|
A visual analog scale constructed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings.
|
Week 6
|
Readiness to perform exercise
Tidsramme: Baseline
|
A visual analog scale constructed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings.
|
Baseline
|
Readiness to perform exercise
Tidsramme: Week 3
|
A visual analog scale constructed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings.
|
Week 3
|
Readiness to perform exercise
Tidsramme: Week 6
|
A visual analog scale constructed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings.
|
Week 6
|
Appetite
Tidsramme: Baseline
|
A visual analog scale constructed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings.
|
Baseline
|
Appetite
Tidsramme: Week 3
|
A visual analog scale constructed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings.
|
Week 3
|
Appetite
Tidsramme: Week 6
|
A visual analog scale constructed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings.
|
Week 6
|
Body composition
Tidsramme: Baseline
|
DXA measurement
|
Baseline
|
Body composition
Tidsramme: Week 3
|
DXA measurement
|
Week 3
|
Body composition
Tidsramme: Week 6
|
DXA measurement
|
Week 6
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Blood pressure
Tidsramme: Baseline
|
Measured in mm Hg
|
Baseline
|
Blood pressure
Tidsramme: Week 3
|
Measured in mm Hg
|
Week 3
|
Blood pressure
Tidsramme: Week 6
|
Measured in mm Hg
|
Week 6
|
Plasma liver enzyme
Tidsramme: Baseline
|
Alanine aminotransferase
|
Baseline
|
Plasma liver enzyme
Tidsramme: Week 3
|
Alanine aminotransferase
|
Week 3
|
Plasma liver enzyme
Tidsramme: Week 6
|
Alanine aminotransferase
|
Week 6
|
Plasma liver enzyme
Tidsramme: Baseline
|
Aspartate aminotransferase
|
Baseline
|
Plasma liver enzyme
Tidsramme: Week 3
|
Aspartate aminotransferase
|
Week 3
|
Plasma liver enzyme
Tidsramme: Week 6
|
Aspartate aminotransferase
|
Week 6
|
Plasma Lipid panel
Tidsramme: Baseline
|
Total cholesterol, LDL, HDL and triglycerides
|
Baseline
|
Plasma Lipid panel
Tidsramme: Week 3
|
Total cholesterol, LDL, HDL and triglycerides
|
Week 3
|
Plasma Lipid panel
Tidsramme: Week 6
|
Total cholesterol, LDL, HDL and triglycerides
|
Week 6
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
27. august 2018
Primær færdiggørelse (Faktiske)
29. august 2019
Studieafslutning (Faktiske)
29. august 2019
Datoer for studieregistrering
Først indsendt
2. marts 2020
Først indsendt, der opfyldte QC-kriterier
2. marts 2020
Først opslået (Faktiske)
4. marts 2020
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
5. marts 2020
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
3. marts 2020
Sidst verificeret
1. marts 2020
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- CVSI-001-2018
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Uafklaret
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hemp arm
-
Main Line HealthAnanda Hemp, Inc.Aktiv, ikke rekrutterendeBrystkræft | Kræft i bugspytkirtlen | Livmoderhalskræft | Kolorektal cancer fase II | Kolorektal cancer stadium III | Kemoterapi-induceret perifer neuropati | LivmoderkræftForenede Stater
-
University of Northern ColoradoRekruttering
-
University of ArkansasTrukket tilbageSund og raskForenede Stater
-
Hôpital NOVOAfsluttetHemiplegi og/eller hemiparese efter slagtilfældeFrankrig
-
Washington University School of MedicineAktiv, ikke rekrutterendeAlzheimers sygdom | Demens af Alzheimer-typenForenede Stater
-
Shandong Suncadia Medicine Co., Ltd.Afsluttet
-
Novartis PharmaceuticalsAfsluttetKronisk spontan nældefeberForenede Stater, Belgien, Det Forenede Kongerige, Tyskland, Ungarn, Spanien, Frankrig, Kalkun, Canada, Tjekkiet, Holland, Polen, Japan, Den Russiske Føderation, Argentina, Danmark, Slovakiet
-
Cyclacel Pharmaceuticals, Inc.AfsluttetAkut myeloid leukæmiForenede Stater
-
Tata Memorial HospitalRekruttering
-
NYU Langone HealthAfsluttetPatientrapporterede resultaterForenede Stater